Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA, Knolhoff BL, Hogg GD, Tang JP, Baer JM, Mpoy C, Lee KB, Alexander KA, Rogers BE, Murphy KM, Hawkins WG, Fields RC, DeSelm CJ, Schwarz JK, DeNardo DG. Hegde S, et al. Among authors: herzog bh. Cancer Cell. 2020 Mar 16;37(3):289-307.e9. doi: 10.1016/j.ccell.2020.02.008. Cancer Cell. 2020. PMID: 32183949 Free PMC article.
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: herzog bh. Clin Cancer Res. 2022 Dec 15;28(24):5254-5262. doi: 10.1158/1078-0432.CCR-22-0308. Clin Cancer Res. 2022. PMID: 36228156 Free PMC article. Clinical Trial.
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study.
Wang-Gillam A, Lim KH, McWilliams R, Suresh R, Lockhart AC, Brown A, Breden M, Belle JI, Herndon J, Bogner SJ, Pedersen K, Tan B, Boice N, Acharya A, Abdiannia M, Gao F, Yoon HH, Zhu M, Trikalinos NA, Ratner L, Aranha O, Hawkins WG, Herzog BH, DeNardo DG. Wang-Gillam A, et al. Among authors: herzog bh. Clin Cancer Res. 2023 Nov 14;29(22):4698. doi: 10.1158/1078-0432.CCR-23-2993. Clin Cancer Res. 2023. PMID: 37960920 No abstract available.
Overcoming Chemotherapy Resistance in SCLC.
Herzog BH, Devarakonda S, Govindan R. Herzog BH, et al. J Thorac Oncol. 2021 Dec;16(12):2002-2015. doi: 10.1016/j.jtho.2021.07.018. Epub 2021 Aug 3. J Thorac Oncol. 2021. PMID: 34358725 Free article. Review.
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.
Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D. Devarakonda S, et al. Among authors: herzog bh. Clin Cancer Res. 2019 Oct 15;25(20):6119-6126. doi: 10.1158/1078-0432.CCR-19-0879. Epub 2019 Jul 12. Clin Cancer Res. 2019. PMID: 31300452 Free PMC article.
Trends in Stage I Lung Cancer.
Singareddy A, Flanagan ME, Samson PP, Waqar SN, Devarakonda S, Ward JP, Herzog BH, Rohatgi A, Robinson CG, Gao F, Govindan R, Puri V, Morgensztern D. Singareddy A, et al. Among authors: herzog bh. Clin Lung Cancer. 2023 Mar;24(2):114-119. doi: 10.1016/j.cllc.2022.11.005. Epub 2022 Nov 21. Clin Lung Cancer. 2023. PMID: 36504141
Competency development in public health leadership.
Wright K, Rowitz L, Merkle A, Reid WM, Robinson G, Herzog B, Weber D, Carmichael D, Balderson TR, Baker E. Wright K, et al. Am J Public Health. 2000 Aug;90(8):1202-7. doi: 10.2105/ajph.90.8.1202. Am J Public Health. 2000. PMID: 10936996 Free PMC article.
14 results